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Abstract
Objectives: To compare the presence and quantity of cervicovaginal HIV among HIV seropositive women with clinical
herpes, subclinical HSV-2 infection and without HSV-2 infection respectively; to evaluate the association between
cervicovaginal HIV and HSV shedding; and identify factors associated with quantity of cervicovaginal HIV.
Design: Four groups of HIV seropositive adult female barworkers were identified and examined at three-monthly intervals
between October 2000 and March 2003 in Mbeya, Tanzania: (1) 57 women at 70 clinic visits with clinical genital herpes; (2)
39 of the same women at 46 clinic visits when asymptomatic; (3) 55 HSV-2 seropositive women at 60 clinic visits who were
never observed with herpetic lesions; (4) 18 HSV-2 seronegative women at 45 clinic visits. Associations of genital HIV
shedding with HIV plasma viral load (PVL), herpetic lesions, HSV shedding and other factors were examined.
Results: Prevalence of detectable genital HIV RNA varied from 73% in HSV-2 seronegative women to 94% in women with
herpetic lesions (geometric means 1634 vs 3339 copies/ml, p = 0.03). In paired specimens from HSV-2 positive women,
genital HIV viral shedding was similar during symptomatic and asymptomatic visits. On multivariate regression, genital HIV
RNA (log10 copies/mL) was closely associated with HIV PVL (b= 0.51 per log10 copies/ml increase, 95%CI:0.41–0.60, p,0.001)
and HSV shedding (b= 0.24 per log10 copies/ml increase, 95% CI:0.16–0.32, p,0.001) but not the presence of herpetic
lesions (b=20.10, 95%CI:20.28–0.08, p = 0.27).
Conclusions: HIV PVL and HSV shedding were more important determinants of genital HIV than the presence of herpetic
lesions. These data support a role of HSV-2 infection in enhancing HIV transmissibility.
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Introduction
Herpes simplex virus type-2 (HSV-2) infection is lifelong and
a common cause of genital ulcers [1–3]. There is strong
epidemiological evidence that HSV-2 infection increases the risk
of HIV acquisition [4–6]. The potential effect of HSV-2 on HIV
infectivity is also of interest. In vitro studies provide evidence of the
effect of HSV-2 infection on HIV replication [7–9] and
epidemiological studies link acute episodes of genital herpes to
temporal increases in HIV plasma viral load [10]. A prospective
study in Ugandan discordant couples has shown that the risk of
HIV transmission is increased in the presence of genital ulcer
disease when the plasma viral load exceeds 1,700 copies/mL [11].
Observational studies have shown an association between HSV-2
genital shedding and HIV genital shedding in some cases but not
others [12–15]. Trials of HSV suppressive therapy in HIV positive
women have shown varying impact on cervicovaginal HIV
shedding [16–22] while a trial of suppressive therapy delivered
to the HIV positive partner in discordant couples found no effect
on HIV transmission to their HIV negative partners [23].
The frequency of recurrent episodes of clinical herpes and of
subclinical viral shedding varies both between individuals and over
time within the same individual [24,25]. While research supports
an association between HSV infection and HIV shedding, it is less
clear whether any effect on HIV infectivity is restricted primarily
to clinical episodes of genital herpes or if HIV transmission is also
enhanced during asymptomatic HSV-2 infection [26]. This is
particularly important since asymptomatic HSV shedding is
observed to occur on up to 28% of days in infected individuals
[27].
The objectives of this study were to compare the presence and
quantity of cervicovaginal HIV in HIV seropositive women living
in Mbeya Region, Tanzania with clinical episodes of herpes,
subclinical HSV-2 infection and without HSV-2 respectively; to
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examine the association between genital shedding of HIV and
HSV-2; and to investigate factors influencing the quantity of HIV
genital shedding.
Methods
Subjects and Study Methods
As part of a study of the determinants of HIV super-infection in
Mbeya Region, Tanzania, an open cohort of 600 female
barworkers aged 18 to 35 years was established in late 2000.
Study procedures have been described previously [28]. Briefly,
behavioural and biological data were collected at baseline and
during 3-monthly follow-up visits for up to 30 months. In this
paper we present data collected from HIV infected participants
between October 2000 and March 2003.
Laboratory Methods (for All Women)
Serological testing and plasma viral load. A diagnostic
algorithm including two different enzyme-linked immunosorbent
assays (HIV-Determine, Abott Laboratories, USA and Enzygnost
HIV 1+2 plus, Behring, Germany) and a Western Blot assay (HIV
Blot 2.2, Genelabs Diagnostics, Singapore) was used to determine
HIV serostatus. Type-specific serological testing for HSV-2 was
also performed by enzyme immune assay (Kalon Biological Ltd,
Aldershot, UK). Syphilis testing was carried out using the Serodia
Treponema pallidum particle agglutination assay (TPPA, Fujirebio
Inc, Tokyo, Japan) and the rapid plasma reagin test (RPR, VD25,
Murex Diagnostics Ltd, Cambridge, UK).
HIV-1 plasma viral load (PVL) was quantified by transcription
polymerase chain reaction (PCR) (Versant 3.0 assay, Bayer
diagnostics, Emeryville, California), with a detection threshold of
50 HIV-RNA copies/ml.
Genital ulcer specimens. A single dry swab was taken from
genital ulcers and multiplex PCR (M-PCR) was used for the
detection of T pallidum, H ducreyi and HSV [29]. Herpetic lesions
were defined as ulcers or vesicles confirmed by M-PCR as positive
for HSV.
Cervicovaginal specimens and vaginal
swabs. Cervicovaginal secretions (CVS) were collected from
all women at every study visit using standard vaginal lavage
procedures [30], by washing with 5 ml of phosphate-buffered
saline. After centrifugation, the cell-free supernatant and cell pellet
were stored separately at 280uC until use. Real time PCR was
used to quantify HIV-1 RNA in the acellular fraction and HIV-1
DNA in the cell pellet of genital secretions as previously described
[31] using primers and probes synthesised by Eurogentec
(Eurogentec SA, Seraing, Belgium). HSV DNA (Roche Molecular
Diagnostics) was also quantified in the acellular fraction of
secretions by real time PCR [32]. Detection thresholds were 250
copies/ml for HIV-1 RNA and HSV DNA, and 5 copies/106 cells
for HIV-1 DNA. Cervicovaginal specimens were also tested for
prostate specific antigen (PSA) using the VITROS immunodiag-
nostic product PSA reagent and calibrator packs on the automaton
Ortho-Clinical Diagnostics VITROS Eci (Ortho-Clinical diag-
nostics, Issy Les Moulineaux, France), and for traces of
haemoglobin using Multistix 8 SG strips (Bayer Diagnostics,
Puteaux, France).
Vaginal swabs were tested for Trichomonas vaginalis by direct
microscopy of a wet mount preparation and Candida albicans by wet
mount preparation and gram stain.
Study Design for Shedding Sub-study
CVS specimens collected from HIV seropositive women at 3-
monthly study visits were excluded from analyses if (i) the woman
had a genital lesion of non-herpetic origin (12 specimens were
excluded for confirmed syphilis and 7 specimens excluded for
chancroid), (ii) there were traces of haemoglobin in the specimen
or (iii) the specimen was positive for PSA. Specimens from (i) were
excluded as HSV shedding may have been influenced by other
ulcerative STIs, and those from (ii) and (iii) were excluded as any
HIV-RNA or HIV-DNA found in the genital tract may not have
been attributable to genital shedding from the woman. Specimens
were categorised into four study groups according to the woman’s
HSV-2 serostatus and the presence or absence of confirmed
herpetic genital lesions at the time of specimen collection. Women
who experienced PCR-confirmed herpetic lesions at one or more
study visits contributed to two study groups: Group 1 (‘‘clinical
herpes’’) included CVS specimens collected in the presence of
herpetic lesions; Group 2 (‘‘subclinical herpes’’), included speci-
mens taken from the same women at follow-up examinations at
least 6 months after or 6 months before the visits at which herpetic
lesions were detected. In Group 3 (‘‘never lesions’’) a random
sample of specimens were taken from HSV-2 seropositive women
who never had herpetic genital lesions or a history of genital
lesions at any of the study visits. Group 4 (‘‘HSV-2 negative’’) was
randomly chosen from specimens taken from women not infected
with HSV-2.
Statistical Analyses
Differences between study groups in proportions of CVS
specimens with HIV-1 (RNA and DNA) and HSV DNA above
the detection threshold were tested using random effects logistic
regression modelling to account for correlations within subjects.
Analyses of quantity of genital viral shedding were restricted to
specimens with viral loads above the threshold of detection.
Logarithmic (log10) transformations were applied to plasma and
genital viral loads for HIV and HSV-2 to obtain approximately
normal distributions, geometric means (GM), and 95% confidence
intervals (95%CI). Differences in mean viral loads between groups
were assessed using a random effects linear regression model to
account for correlations within subjects. Correlations between viral
loads (plasma and genital) were assessed using Spearman’s rank
correlation coefficient.
The effect of genital herpetic lesions on HIV and HSV shedding
was assessed by carrying out matched pair chi-squared tests on
detection of virus, and a paired t-test on the quantity of shedding,
for paired samples collected from the same women during clinical
and subclinical phases of herpes, randomly selecting a single
sample result if more than one eligible sample was available.
Sample size calculations used the log scale for HIV shedding,
assuming a within-women difference of 0.3 log copies/mL
between episodes with herpetic lesions and those without herpetic
lesions, and a standard deviation of 0.6 log copies/mL. With 60
women providing paired samples, the analysis had a 80% power to
detect a difference of 0.3 as significant at the 5% level (which
corresponds to a doubling of the HIV shedding in women with
clinical lesions).
Initial analyses suggested that HSV shedding was a strong
determinant of genital HIV shedding. We regrouped specimens of
HSV-2 seropositive women in the subclinical and never lesions
groups according to the presence of HSV shedding (asymptomatic
HSV shedders) or absence of HSV shedding (HSV non-shedders).
We then used random effects linear regression, accounting for
multiple observations from the same individual, to examine the
association of log-transformed HIV genital viral loads with HSV
shedding status as well as other potential risk factors, including
age, laboratory-diagnosed non-ulcerative sexually transmitted
infections (STI), signs or symptoms of sexually transmitted diseases
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(STD), enlarged lymph nodes and HIV plasma viral load. In this
analysis, specimens with HIV or HSV genital viral load below the
threshold of detection were assigned a value of half the threshold.
Analyses were performed using Stata 11.0 (Stata Corporation,
Texas, USA). The study was approved by the national ethics
review committee of the National Institute for Medical Research
of the United Republic of Tanzania and the LSHTM Ethics
Committee (Approval 668). It was conducted within the frame-
work of the Mbeya Medical Research Programme. All participants
provided written, informed consent to participate in the study.
Results
Characteristics of Participants
Analyses were based on 221 eligible CVS samples from 131
HIV seropositive women. The four study groups comprised 57
women at 70 study visits with clinically manifest genital herpes
(Group 1), 39 of the same women at 46 study visits when they did
not have visible ulcers (Group 2), 55 HSV-2 seropositive women at
60 study visits who were never observed with herpetic lesions
(Group 3), and 18 women at 45 study visits who were HSV-2
seronegative (Group 4) (Table 1).
Thirty-five women contributed to both Groups 1 and 2; four
other women in Group 2 were not sampled at the time of clinical
herpes. Three women were HSV-2 seronegative (Group 4) and
later seroconverted, two with an episode of clinical herpes (Group
1) and one with no episode of clinical herpes (Group 3). Thirty-
three women contributed more than one specimen to the same
study group (up to 7 specimens from one HSV-2 seronegative
woman).
Mean age was around 28 years for HSV-2 positive women and
25 years for HSV-2 negative women. Slightly higher proportions
of women were using hormonal contraception among those who
had never had lesions, and those who were HSV-2 negative, but
this difference was not statistically significant (p = 0.35).
Geometric mean PVL was lowest (5,830 copies/ml) in samples
from women uninfected with HSV-2 and highest (24,400 copies/
ml) in samples from women with confirmed herpetic lesions.
TPPA seropositivity, indicating past or current syphilis, was also
lower in the HSV-2 uninfected group (p,0.001), and C Albicans
was most common in the never lesions group (p = 0.08), but other
STI or clinical signs of STD at the time of specimen collection did
not differ significantly by study group (Table 1).
Genital Shedding of HIV and HSV by Study Group
The prevalence of detectable genital HIV RNA was lowest in
the HSV-2 negative group (73%) and highest in the clinical herpes
group (94%) (Table 1). The genital HIV RNA viral load in those
with detectable virus showed a similar trend across the four
groups, with the lowest quantity in the HSV-2 negative group
Table 1. Characteristics of participants and cervicovaginal viral shedding by study group.
Factor Study group
Clinical herpes Subclinical herpes Never lesions HSV-2 negative
Women N=57 N=39 N=55 N=18 p-value1
Age Mean (SD) 28.1 (4.20) 28.8 (4.13) 27.2 (4.27) 24.6 (4.34) 0.001 2
Hormonal contraceptive use 17 (30%) 8 (21%) 20 (36%) 7 (39%) 0.35
Specimens N= 70 N=46 N= 60 N=45
Plasma HIV-1 RNA
Geo mean (95% CI) 24400 (16400–36300) 16300 (9900–26900) 10550 (6900–16100) 5830 (3540–9600) ,0.0012
Presence of STI (%)
TV 9 (13%) 4 (9%) 8 (13%) 2 (4%) 0.49
CA 21 (30%) 9 (20%) 27 (45%) 16 (36%) 0.08
TPPA 32 (46%) 22 (48%) 33 (55%) 8 (18%) ,0.001
RPR 11 (16%) 5 (11%) 9 (15%) 2 (4%) 0.28
Warts 10 (14%) 9 (20%) 5 (8%) 3 (7%) 0.8
Cervicitis 9 (13%) 7 (15%) 9 (15%) 4 (9%) 0.88
Vaginal discharge 28 (40%) 21 (46%) 27 (45%) 28 (62%) 0.2
Lymphadenopathy 19 (27%) 8 (17%) 8 (13%) 6 (13%) 0.19
CVS HIV RNA 66 (94%) 41 (89%) 49 (82%) 33 (73%) 0.13
Geo mean3 (95% CI) 3339 (2410–4626) 2460 (1653–3664) 1908 (1319–2758) 1634 (1096–2436) 0.025 2
CVS HIV DNA4 63 (100%) 43 (98%) 43 (90%) 43 (100%) 0.002
Geo mean3 (95% CI) 252 (182–349) 152 (115–201) 141 (93–213) 143 (101–203) 0.0252
CVS HSV DNA 54 (77%) 9 (20%) 7 (12%) – ,0.001
Geo mean3 (95% CI) 4260 (2384–7613) 4336 (1245–15102) 1392 (288–6729) – 0.372
SD, standard deviation; STI, sexually transmitted infection; TV, Trichomomas vaginalis; CA, Candida albicans; TPPA, Treponema pallidum particle agglutination assay; RPR,
rapid plasma reagin test; Geo mean, geometric mean in copies/ml (HIV RNA and HSV DNA) or copies/106 cells (HIV DNA); CVS, cervico-vaginal lavage specimen.
1p-value from random effect logistic regression accounting for correlation within subjects.
2p-value from random effects linear model on log-transformed viral load accounting for correlation within subjects.
3Excluding data below the minimum detectable threshold.
4Missing values for 7 with clinical herpes, 2 with sub-clinical herpes, 12 with never lesions, and 2 HSV-2 negative.
doi:10.1371/journal.pone.0059037.t001
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(GM=1634 copies per ml) and the highest in the clinical herpes
group (GM=3339 copies per ml) (p,0.025).
The prevalence of detectable genital HIV DNA also varied
across study groups (p = 0.002). The pattern was less clear than for
HIV RNA, but the highest viral load was seen in the clinical
herpes group (GM=252 copies per 106 cells) and the lowest in the
never lesions group (GM=141 copies per 106 cells) (Table 1).
All women with detectable genital HIV RNA also had
detectable plasma HIV RNA. Among women with detectable
genital HIV RNA, quantities of plasma and genital HIV RNA
were significantly correlated (N= 189, Spearmans r = 0.49,
p,0.001).
As expected, the prevalence of detectable genital HSV DNA
varied substantially between the three study groups of HSV-2
positive women, with a much higher prevalence among women
with clinical herpes (77%) than in the subclinical herpes (20%) and
never lesions (12%) groups (p,0.001). HSV DNA viral load
showed a similar, though non-significant trend (Table 1).
Of the 35 women who had specimens taken during clinical
episodes of herpes and also at visits when they were asymptomatic,
30 (86%) had detectable HIV RNA on both occasions, while all 29
women with paired specimens analysed for HIV DNA were
positive on both occasions. There was no evidence of a difference
in the quantity of genital HIV shed between clinical and
subclinical phases of herpes (Table 2). Although 23 (66%) of the
35 women had detectable genital HSV DNA during clinical
herpes, only 7 (20%) had detectable HSV DNA during the
subclinical phase (p,0.001), with 5 (14%) shedding on both
occasions.
Association between Genital HIV Shedding and Genital
HSV Shedding
To explore whether signs of clinical herpes or HSV-2 viral
shedding were more important determinants of HIV shedding, we
re-categorised the specimens into four new groups: clinical herpes,
HSV-2 seropositive with detectable genital HSV DNA shedding
(asymptomatic HSV shedders), HSV-2 seropositive without de-
tectable genital HSV shedding (HSV non-shedders at that visit),
and HSV-2 seronegative. In all four groups, the majority of
specimens had detectable HIV RNA and HIV DNA, and the
prevalence was highest in samples taken during clinical or
subclinical shedding episodes (Table 3). Overall, the prevalence
and quantity of genital HIV-1 RNA and DNA shedding differed
by sub-group (Table 3). Genital HIV-1 RNA and DNA viral loads
were at least as high among asymptomatic HSV shedders as
among specimens collected during episodes of clinical herpes.
Similarly genital viral load was similar between HSV non-shedders
and HSV-2 seronegative women.
Among specimens with HSV DNA shedding (with or without
lesions), the genital viral loads of HIV RNA and HSV DNA were
positively correlated (n = 86, r = 0.47, p,0.001). The correlation
of genital HIV DNA and HSV DNA was weaker (n = 78, r = 0.24,
p = 0.03), as was the correlation between plasma HIV RNA and
genital HSV DNA (n= 78, r = 0.24, p = 0.03). A positive
correlation between genital and plasma viral loads of HIV was
seen in all women (Fig. 1 and Fig. 2). While the slopes of the
regression lines were similar, the intercept was higher in the
clinical herpes and HSV shedding groups indicating that, for any
given PVL, the genital shedding of HIV was higher in those who
were also shedding HSV-2.
Risk Factors for Genital HIV Shedding
Genital HIV RNA viral load increased with quantity of HIV
PVL (p,0.001) and presence and quantity of genital HSV DNA
(Table 4). Although the quantity of genital HIV RNA was higher
in specimens from HSV-2 seropositive women (p= 0.009) and
those with herpetic lesions (p = 0.002), the association with
herpetic lesions was no longer statistically significant after
adjusting for age, PVL and the quantity of genital HSV DNA
(Table 4). The quantity of genital HIV RNA was unrelated to the
presence of STI, signs or symptoms of other STD or enlarged
lymph nodes (data not shown), or to the use of hormonal
contraception.
Similarly, genital HIV DNA viral load increased with both HIV
PVL (p,0.001) and genital HSV DNA viral load (Table 4).
Although genital HIV DNA was more commonly detected in the
presence of clinical herpes (p = 0.004), this association was no
longer statistically after adjusting for age, PVL and the quantity of
genital HSV DNA. The quantity of genital HIV DNA was
unrelated to the presence of STI, signs or symptoms of other STD
or enlarged lymph nodes (data not shown), or to the use of
hormonal contraception.
Table 2. Cervicovaginal HIV-1 and HSV viral load in 35 women during the clinical and subclinical stages of herpes.
Viral shedding N
Number (%) with detectable virus Geometric mean (95%
CI) p-value1 p-value2
Clinical herpes Subclinical herpes
CVS HIV-1 RNA3 Number (%) 35 31 (89%) 32 (91%) 0.56
CVS HIV-1 RNA3 Geometric mean (95% CI) 35 3137 (1914–5143) 2800 (1804–4345) 0.72
CVS HIV-1 DNA3,4 Number (%) 29 29 (100%) 29 (100%) 1.0
CVS HIV-1 DNA3,4 Geometric mean (95% CI) 29 157 (90–221) 157 (110–221) 0.99
CVS HSV DNA3 Number (%) 35 23 (66%) 7 (20%) 0.0003
CVS HSV DNA3 Geometric mean (95% CI) 35 3369 (1210–9380) 4236 (1351–13278) 0.24
Analyses restricted to women with samples in both the clinical and the subclinical groups.
1p-value from matched pairs chi-squared test.
2p-value from matched pairs t-test on logged values.
3Geometric mean in copies/ml (HIV RNA and HSV DNA) or copies/106 cells (HIV DNA), excluding data below the minimum detectable threshold at half the detectable
level.
4Six women did not have HIV DNA samples tested (five with clinical herpes, and one with subclinical herpes) and are excluding from this comparison.
doi:10.1371/journal.pone.0059037.t002
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Discussion
In this study we determined the frequency and quantity of
cervicovaginal HIV and HSV using specimens collected from 131
HIV infected women who were followed up every three months
for up to 30 months. The prevalence of detectable genital HSV
DNA in asymptomatic HIV positive women was similar to studies
from elsewhere in Africa [33] and, as in other studies, there was
a strong correlation between genital and plasma HIV viral loads
[15].
The main objective of our study was to determine whether
genital shedding of HIV occurred more frequently in the presence
of genital herpetic lesions. A strength of the study was the long
follow-up period, providing an opportunity to observe women
both during and between clinical episodes of herpes. Clinical
herpes was associated with higher levels of genital HIV shedding,
but only partially as there were episodes of herpetic ulceration
where HSV genital shedding was not recorded, and conversely
episodes of HSV genital shedding in asymptomatic women. In the
multivariate analysis, we clearly saw that herpetic ulcers were not
independently associated with genital shedding of HIV RNA
(coefficient =20.10, p = 0.27), whereas there remained a clear
association between HSV genital shedding and genital shedding of
HIV RNA (coefficient = +0.24, p,0.001), suggesting that this
increase was related to the quantity of genital HSV and the HIV
plasma viral load rather than to the presence or absence of
Table 3. Cervicovaginal HIV-1 RNA, HIV-1 DNA and HSV DNA viral load by HSV-2 group.
HSV-2 group
Genital viral
Shedding
Clinical
Herpes
Subclinical
HSV shedders
Subclinical
Non shedders HSV-2 negative p-value1
HIV-1 RNA N=70 N=16 N=90 N=45
Number (%) 66 (94%) 16 (100%) 74 (82%) 33 (73%) 0.11
Geo mean 2 (95% CI) 3339 (2410–4626) 4326 (2076–9012) 1840 (1392–2433) 1634 (1096–2436) 0.002
HIV-1 DNA N=63 N=15 N=77 N=43
Number (%) 63 (100%) 15 (100%) 71 (90%) 43 (100%) 0.04
Geo mean 2 (95% CI) 252 (182–349) 260 (131–517) 130 (100–203) 143 (101–203) 0.003
HSV DNA N=70 N=16
Number (%) 54 (77%) 16 (100%) NA NA 0.03
Geo mean 2 (95% CI) 4260 (2383–7613) 2637 (1064–6541) NA NA 0.4
IQR, interquartile range; CI, confidence interval.
1p-values from random effects logistic regression model, or random effects linear regression model.
2Geometric mean in copies/ml (HIV RNA and HSV DNA) or copies/106 cells (HIV DNA), excluding data below the minimum detectable threshold level.
doi:10.1371/journal.pone.0059037.t003
Figure 1. Relationship between HIV RNA genital shedding and HIV plasma viral load in women with herpetic lesions, asymptomatic
women with and without HSV genital shedding and HSV-2 seronegative women.
doi:10.1371/journal.pone.0059037.g001
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herpetic lesions. In paired specimens taken from women with
clinical herpes and from other study visits when they were
asymptomatic, no difference was seen in HIV genital shedding at
the two visits. When the original study groups were rearranged to
examine the effect of genital HSV shedding, there was a clear
difference in HIV genital shedding between HSV shedders and
non-shedders, but no additional increase in HIV shedding in those
with clinical herpes. Similarly, when risk factors for HIV genital
shedding were examined in a multivariate regression analysis, the
quantity of genital HIV RNA or DNA was significantly associated
with HIV plasma viral load and HSV shedding, but after
adjustment for these factors was not associated with clinical herpes.
Our findings are consistent with results from a study carried out
in Bangui, Central African Republic, where among HIV positive
women shedding HSV, there was a significant correlation between
genital HIV RNA shedding and genital shedding of HSV [14]. A
similar positive correlation between cervical HSV shedding and
the quantities of cervical HIV-1 RNA and DNA was seen in
a cross-sectional study of 200 women attending family-planning
clinics in Mombasa, Kenya, and this was significant even after
controlling for differences in CD4 count and plasma viral load
[13]. Baseline data from a randomised controlled trial of herpes
episodic treatment in Ghana and Central African Republic
showed that, among 180 HSV-2/HIV-1 co-infected women,
genital HIV RNA was detected more frequently and at higher
median viral loads among women with genital HSV-2 infection
(i.e. HSV-2 ulcers or HSV-2 in CVS) than women without any
genital HSV-2 infection [34]. However, in a study of 214
Zimbabwean sex workers, genital HIV-1 RNA shedding increased
with HIV plasma viral load but did not differ in women with or
without HSV shedding, although the HSV shedding was not
quantified [15]. A study in men and women in Thailand showed
no association between the quantities of HIV shed and the
presence of either HSV shedding or herpetic lesions [35].
The observational design of these studies limits inferences about
causality, but stronger evidence concerning the effect of herpes on
HIV infectivity comes from seven recently completed randomised
controlled trials of herpes suppressive therapy. Four trials, using
valacyclovir or high dose acyclovir (800 mg b.i.d.), found
significant reductions in PVL as well as significant reductions in
rectal and cervicovaginal HIV-1 RNA concentrations [16–19].
Trials of acyclovir 400 mg b.i.d have shown less effect. Two found
no reduction in cervico-vaginal HIV-1 RNA detection [20,21],
possibly attributable to sub-optimal adherence and the other found
a reduction in frequency of cervico-vaginal HIV-1 RNA detection
and plasma HIV-1 RNA load but no effect on viral load among
those with detectable shedding [22]. Moreover, a trial of acyclovir
(400 mg b.i.d.) delivered to the HIV positive partner in discordant
couples (‘‘Partners in Prevention’’) found no effect on HIV
transmission to their HIV negative partners, although there was
some evidence that acyclovir reduced risk of HIV-1 disease
progression to either CD4 count below 200 cells/mL, use of ART
or death (hazard ratio(HR) = 0.84, 95%CI 0.71–0.98) [36].
Our results are consistent with previous reports of an association
between HSV-2 shedding and HIV PVL, and suggest that clinical
and subclinical herpetic reactivations might increase genital HIV
shedding not only through a direct viral interaction at the genital
level, but also through their systemic effect on plasma HIV viral
load [37]. In our study, HIV plasma viral load was the strongest
determinant of HIV genital shedding, and higher plasma viral
loads were observed in women with herpetic ulcers and
asymptomatic herpes than in uninfected women.
In this study we used cervicovaginal specimens as a marker of
genital shedding, and did not find evidence of increased HIV
shedding in the presence of genital lesions. However, HIV
shedding may also occur directly from a herpetic lesion, and we
cannot exclude the possibility that overall HIV infectivity is
increased in the presence of lesions, particularly as 64% of herpetic
lesions seen in this study were found on the vulva [38]. The
Figure 2. Relationship between HIV DNA genital shedding and HIV plasma viral load in women with herpetic lesions, asymptomatic
women with and without HSV genital shedding and HSV-2 seronegative women.
doi:10.1371/journal.pone.0059037.g002
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quantification of both the HIV shedding and the HSV shedding
were taken from the dilution of the CVS supernatant, and these
are dependent on the amount of vaginal fluid in the vaginal lavage.
Genital specimens from women with ulcers of other confirmed
aetiology (T pallidum or H ducreyi) were excluded from this analysis,
as were specimens with traces of blood or semen, although we
cannot rule out the possibility that some HIV or HSV detected in
CVS originated from infected sexual partners. Some CVS were
collected from women with non-ulcerative STI, and this may have
led to underestimation of the association between herpetic lesions
and HIV shedding, as cervicovaginal secretion of HIV-1 has been
associated with the presence of non-ulcerative STI such as
gonorrhoea and Chlamydia and found to decrease after effective
treatment [39–41]). However, in this study the presence of other
STI was not associated with increased HIV shedding (data not
shown), and all symptomatic participants were given treatment for
all STI free-of-charge throughout the study.
Increased genital HIV-1 viral load has been shown to be
associated with immunosuppression in some studies [14,41] but
not others [42]. In our study, CD4 counts were not available, but
most women had plasma HIV-1 RNA ,30,000 copies/ml, and
few specimens were collected at a time when lymph nodes or other
clinical signs or symptoms of HIV-related disease were present.
Furthermore, the HSV type was not determined in this study and
some of the detected HSV may have been HSV-1 rather than
HSV-2.
In conclusion, this study adds to the accumulating evidence that
HSV-2 infection increases genital shedding of HIV, and may
therefore increase the infectivity of HIV infected individuals to
their sexual partners. Our data suggest that the increase in HIV
shedding is related to the quantity of HSV shedding rather than to
the presence of clinical lesions of herpes. These findings emphasise
the importance of developing and evaluating effective interven-
tions to control herpes in populations where HSV-2 may account
for a substantial proportion of HIV transmission.
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